Full steam ahead: Dexcom brings its flagship G6 CGM to veterans, creates first registry for in-hospital use and signs collaboration with University of Virginia.

With AIDS and HCV under control, companies large and small are looking to protect the blood supply from a range of known and as yet unknown pathogens, which pose potential threats. Near-term attention is focusing on emerging pathogen inactivation technologies, which are moving closer to the clinic, even as questions linger about their cost effectiveness and toxicity.